Argiris Symeonidis
University of Patras
H-index: 47
Europe-Greece
Top articles of Argiris Symeonidis
The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer
bioRxiv
2024
Argiris Symeonidis
H-Index: 28
Delayed diagnosis of a primary diffuse large B-cell lymphoma of the humeral head, presenting as pathological fracture: a case report and review of the literature
JSES Reviews, Reports & Techniques
2024/1/26
Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML
2024/3/21
Argiris Symeonidis
H-Index: 28
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
2024/3/17
Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer
Plos one
2024/2/27
Argiris Symeonidis
H-Index: 28
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece
2024/2/26
Maria Dimou
H-Index: 13
Argiris Symeonidis
H-Index: 28
Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study
British Journal of Haematology
2024/2/11
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
American Journal of Hematology
2024/1/31
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ
Blood Advances
2024/1/23
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece
Journal of Clinical Medicine
2024/1/19
Argiris Symeonidis
H-Index: 28
Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels
Cureus
2023/12/2
Argiris Symeonidis
H-Index: 28
P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
HemaSphere
2023/8/1
Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries
Leukemia
2023/3
Theodoros P Vassilakopoulos
H-Index: 23
Eleftheria Hatzimichael
H-Index: 25
Maria Dimou
H-Index: 13
Argiris Symeonidis
H-Index: 28
P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 …
HemaSphere
2023/8/1
Evangelos Terpos
H-Index: 61
Argiris Symeonidis
H-Index: 28
Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in …
Leukemia
2023/12
PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY
HemaSphere
2023/8/1
Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry
British Journal of Haematology
2023/2
Argiris Symeonidis
H-Index: 28
Alex Smith
H-Index: 9
Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis
Blood
2023/11/28
PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
HemaSphere
2023/8/1
Argiris Symeonidis
H-Index: 28
Methylation Patterns of Fetal Hemoglobin Regulating Genes in High-Risk (HR)-MDS Patients Following Treatment with Azacytidine
Blood
2023/11/28
Co-Authors
H-index: 80
Kastritis Efstathios OR Castritis Efstathios
National and Kapodistrian University of Athens
